Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01463163
Other study ID # PATRASCARDIOLOGY-8
Secondary ID
Status Completed
Phase Phase 4
First received October 27, 2011
Last updated April 9, 2012
Start date October 2011
Est. completion date April 2012

Study information

Verified date April 2012
Source University of Patras
Contact n/a
Is FDA regulated No
Health authority Greece: Ethics Committee
Study type Interventional

Clinical Trial Summary

This is a single-center, randomized, single-blind, investigator-initiated, pharmacodynamic study with a parallel design. Patients with ST elevation myocardial infarction, undergoing primary percutaneous coronary intervention will be randomized after informed consent, in a 1:1 ratio to the following treatment groups:

Group Α: Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD)starting 12±6 hours post LD, until Day 5 (5 days after randomization) Group Β: Prasugrel 60 mg LD followed by 10mg x1 MD starting 24 hours post LD, until Day 5 (5 days after randomization).

Platelet reactivity assessment will be performed at randomization (Hour 0) and at 1, 2, 6, 24 hours after randomization, and on Day 5. Documentation of major adverse cardiac events (death, myocardial infarction, stroke, revascularization procedure with PCI or CABG)and serious adverse events (bleeding, other adverse events)will be performed until Day 5.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date April 2012
Est. primary completion date April 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 95 Years
Eligibility Inclusion Criteria:

1. Age =18 years old

2. Patients with STEMI undergoing primary PCI with stenting

3. Informed consent obtained in writing

Exclusion Criteria:

- Pregnancy

- Breastfeeding

- Inability to give informed consent or high likelihood of being unavailable until the Day 5

- Prior PCI performed within 30 days prior to randomization

- Cardiogenic shock

- Major periprocedural complications (death, stent thrombosis, vessel perforation, arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous antiarrhythmic agents, respiratory failure requiring intubation, vascular injury (arteriovenous shunt, retroperitoneal bleeding), major bleeding (need for bood transfusion or drop in haemoglobin post-PCI by = 5 gr/ dl or intracranial bleeding).

- Unsuccessful PCI (residual stenosis > 30% or flow < ???? 3) or planned staged PCI in the next 5 days after randomization

- Requirement for oral anticoagulant prior to the Day 5 visit

- Current or planned therapy with other thienopyridine class of ADP receptor inhibitors.

- Known hypersensitivity to prasugrel or ticagrelor

- History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 6 months.

- Other bleeding diathesis, or considered by investigator to be at high risk for bleeding.

- Any previous history of ischemic stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).

- Thombocytopenia (<100.000 / µL) at randomization

- Anaemia (Hct <30%) at randomization

- Polycytaemia (Hct > 52%) at randomization

- Periprocedural IIb/IIIa inhibitors administration

- Severe allergy to contrast agent, unfractionated heparin, enoxaparin or bivalirudin that cannot be adequately premedicated.

- Recent (< 6 weeks) major surgery or trauma, including GABG.

- Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.

- Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A inducers (rifampin /rifampicin, phenytoin, carbamazepine).

- Increased risk of bradycardiac events.

- Dialysis required.

- Severe uncontrolled chronic obstructive pulmonary disease

- Known severe hepatic impairement

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Prasugrel
Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
Ticagrelor
Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours

Locations

Country Name City State
Greece Cardiology Department Patras University Hospital Rio Achaia

Sponsors (1)

Lead Sponsor Collaborator
University of Patras

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary Platelet reactivity Platelet reactivity Platelet assessed by VerifyNow P2Y12 assay 1 hour post randomization 1hour No
Secondary Platelet reactivity Platelet Reactivity assessed by Multiplate analyzer assay 1 hour post randomization 1 hour No
Secondary Platelet reactivity Platelet reactivity assessed by the VerifyNow assay 2 hours post randomization 2 hours No
Secondary Platelet reactivity Platelet Reactivity assessed by Multiplate analyzer 2 hours post randomization 2 hours No
Secondary Platelet reactivity Platelet Reactivity assessed by VerifyNow P2Y12 assay 6 hours post randomization 6 hours No
Secondary Platelet reactivity Platelet Reactivity assessed by Multiplate analyzer 6 hours post randomization 6 hours No
Secondary Platelet reactivity Platelet Reactivity assessed by VerifyNow P2Y12 assay 24 hours post randomization 24 hours No
Secondary Platelet reactivity Platelet Reactivity assessed by Multiplate analyzer 24 hours post randomization 24 hours No
Secondary Platelet reactivity Platelet Reactivity assessed by VerifyNow P2Y12 assay 5 days post randomization 5 days No
Secondary Platelet reactivity Platelet Reactivity assessed by Multiplate analyzer 5 days post randomization 5 days No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02808039 - Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial N/A
Completed NCT01961856 - Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor. Phase 3
Recruiting NCT03525145 - Platelet Reactivity And Clinical ThrombotIC Events Study
Completed NCT01463150 - Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI) Phase 4
Recruiting NCT03614832 - Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD Phase 4
Completed NCT01835353 - High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI) Phase 3
Completed NCT04001894 - Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease Phase 4
Recruiting NCT05773989 - Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy Phase 4
Completed NCT01511471 - Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis Phase 3
Completed NCT00976196 - Platelet Hyperreactivity Project N/A
Completed NCT00827346 - Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty Phase 2/Phase 3
Recruiting NCT05367336 - Platelet Reactivity With Fentanyl, Morphine, or no Narcotic Early Phase 1
Completed NCT03679091 - Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD. Phase 4
Recruiting NCT05657041 - Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease Phase 2/Phase 3